Introduction
Patient reported outcomes (PRO) are defined as 'any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patients response by anyone else. ' 1 As a measurement of patients' experiences, PRO are key assessments in patient centered research. Dyspnea, or the sensation of breathlessness, is one of the most commonly measured PRO's in acute heart failure (AHF) clinical trials. The sensation of difficulty breathing or shortness of breath compels patients with AHF to seek medical care. 2, 3 Early and persistent relief of dyspnea has been associated with improved outcomes. 4e7 Although dyspnea is significantly improved after initial therapy, 8 a substantial number of patients continue to have dyspnea during hospitalization. 4e6 As such, its relief is important to both patients and caregivers, especially with the current focus on patient centered outcomes. 9 As a subjective, patient reported symptom, how exactly to assess and measure dyspnea continues to be debated. 9e11 While clinical trials now use a more standardized method of dyspnea assessment d formal training, standardized position, only after a period of rest 7 d use of dyspnea as a clinical trial endpoint has fallen out of favor, in part due to the difficulty of demonstrating a significant difference between investigational agents and usual care. 12, 13 However, as the predominant AHF symptom, relief from dyspnea is important to patients. Similar to the measurement of pain, proper measurement of dyspnea in AHF is needed. 9 Unlike COPD or asthma however, how to best measure dyspnea in AHF remains challenging. Which scale to use, when and how often to measure dyspnea lacks convincing data or universal consensus. Furthermore, the accuracy and reliability of such measures continues to be debated. 10 Nevertheless, as the most common presenting symptom in AHF, assessment of dyspnea remains important. Specifically, what degree of improvement is considered a clinically important difference to patients has not been extensively investigated.
The minimal clinically important difference (MCID) is the "smallest benefit of value to patients." 14 As clinicians and patients
may disagree on what is clinically meaningful, understanding patients' perspective is critical for a patient centered outcome. Knowing the MCID also informs clinical trial design, providing the minimal effect size. Despite the importance of dyspnea to patients and its near universal presence in AHF patients, the minimal clinically important difference (MCID) in dyspnea via various measurement scales has not been well studied. 7 In our primary paper, we sought to determine changes in dyspnea, using a standardized approach, in ED AHF patients treated with usual therapy. 8 We described the degree of dyspnea improvement in ED patients with AHF and how patient positioning impacted the patients quantification of dyspnea. 8 Briefly, we found most patients (76%) report improvement after 6 h of usual therapy. Furthermore, 47% of patients reported worse symptoms when evaluated lying down compared with sitting upright. Although we found a significant correlation between the 5-point Likert and VAS scales, there was less agreement with the 7-point Likert. 8 Importantly, we did not ascertain the MCID. Thus, the objective of this paper was to determine the MCID in patients with AHF presenting to the emergency department (ED).
Methods
URGENT Dyspnea was IRB or ethics committee approved at every site. Details regarding the URGENT Dyspnea (Ularitide Global Evaluation in Acute Decompensated Heart Failure) study design and main study results have been previously presented. 8 Briefly,
URGENT Dyspnea was a multi-center, prospective observational study that enrolled 776 patients from 17 countries involving 35 sites from January through August of 2007. The primary objective was to determine changes in patient reported dyspnea over 6 h, capturing patients shortly after ED presentation. At the time of the original study, dyspnea was a major endpoint for every large AHF therapeutic trial. However, how to best measure dyspnea and the time course of its improvement, especially in the ED setting, had not been well studied. At that time, AHF trials were enrolling patients 24e48 h after hospitalization. If dyspnea improved rapidly, capturing patients earlier may be critically important. Thus, our goal was to describe the time course of dyspnea in a broad ED AHF population. Patients were assessed at baseline and then again at 6 h. Six hours was chosen to better capture the time course of dyspnea and also to maintain the study as an ED-based study.
Establishing the MCID
There are multiple techniques to define the MCID; broadly, they may be categorized into three groups: 1) Distribution-based method, 2) Anchor based and the 3) Delphi method. No method has been universally defined as superior to the others. Briefly, the distribution based utilizes the standard deviation or standard error of the mean with a prespecified definition of deviation from the mean as the MCID or a measure at least one standard error away. The anchor based method uses one scale as the anchor for another, different scale. However, establishing what constitutes a MCID on one scale to use as an anchor has been debated. No consensus exists. The final method is a combination of literature review and expert opinion to reach consensus. Although we did not utilize a formal Delphi method, the authors were in consensus regarding the anchor.
Participants
To best replicate 'real-world' conditions, eligibility criteria were intentionally kept broad. Any patient 18 years and older with signs and symptoms of heart failure and the ability to self-assess dyspnea were eligible. However, they had to be enrolled within 1 h of first physician contact. Given the short time frame, patients with dyspnea presumed attributable to AHF were approached, consented, and then enrolled. Treatment and management were directed by the patients' clinical care team: there were no prespecified protocols or treatment interventions. Demographic, clinical, and treatment data were collected per standardized case report form. The site principal investigator, who had full access to all available clinical data, determined the final diagnosis of AHF.
Dyspnea assessment instruments
At 6 h after enrollment, patients were asked about the severity of their dyspnea. They were asked to report via commonly used scales in AHF. The 7-point Likert scale: "Compared to how you felt when you first arrived, do you now feel your breathing is: Markedly worse, moderately worse, minimally worse, no change, minimally improved, moderately improved, markedly improved?" We utilized the anchor based method of establishing the MCID, which compares the change in a patient reported outcome to another, different instrument. A one-category change of "minimally worse" or "minimally improved" was used as the criterion standard for the MCID in this study. This standard was chosen based on previously published work in AHF and the MCID, 15 which was based on prior work in the assessment of pain. Two other scales were used to assess dyspnea at both time zero and 6 h later; a 5-point Likert scale ("I am not short of breath (short of breath)", "Mildly short of breath", "Moderately short of breath", "Severely short of breath", "Very Severely short of breath") and a 100 mm VAS, with 0 as "I am not breathless at all" to 100 mm as "I am the most breathless I have ever been." Per protocol, this 100 mm line was divided into 10 equal 1 cm increments and scored accordingly. Patients were specifically asked: "How short of breath do you feel?" prior to their response.
Despite each of these instruments being used in AHF clinical trials, 7,13,18e21 their reliability and validity in the setting of AHF has not been well studied. 9, 22 This actually led to the design and conduct of the primary URGENT Dyspnea study. 8 Our own work suggests potentially significant differences in response between scales. 10 Despite the lack of study, these scales continue to be used and are recognized by regulatory agencies for potential approval of novel therapeutics. Thus, this previous work led to the design of the current analysis.
Outcome measures
The main outcome measures were the change in visual analog scale (VAS) and 5-point Likert scale from baseline to 6-h assessment relative to a 1-category change response in the 7-point Likert scale ('minimally worse', 'no change', or 'minimally better').
Both the 5-point Likert and VAS were measured in two positions to ascertain the effect of position on patient reported dyspnea. Patients were initially assessed in the upright position (seated, head of bed ! 60 ). If patients reported "severely" or "very severely" by the 5-point Likert, the supine position was not assessed due to safety concerns. For any other score, patients were placed in the supine position (head of bed 20 ) and after an equilibration period of 120 s, both the 5-point Likert and 100 mm VAS were repeated.
Statistical analysis plan
We utilized the anchor based method to determine the MCID. 14 To the best of our knowledge, the only other study to explore the MCID in AHF from the ED perspective also utilized the anchor based method. 15 This method uses another measure of improvement e the 7-point Likert scale e as the 'anchor' to associate change via another numerical scale.
14 As we were not certain what the MCID would be, we did not pre-specify the effect size. However, using conservative estimates, we have 80% power to detect a 10 mm change in VAS corresponding to a 1 point minimal improvement by Likert, assuming a group size of 64 subjects and type 1 error controlled at 0.05 (two-sided).
Patients were divided into 3 groups based upon the 7-point Likert; 1) those reporting "No Change", 2) those reporting "Minimally worse", and 3) those reporting "Minimally improved". Using this grouping, all other categories were excluded. To ascertain whether greater or lesser changes had value, additional analyses were performed by dividing the patients into three groups based on any reported improvement, any worsening, or no change in the 7-point Likert, thus using all eligible subjects.
Baseline characteristics including frequencies and percentages for categorical variables and means and standard deviations for continuous variables, were calculated and compared between the groups using Fisher's exact tests and one-way analysis of variance (ANOVA) models, as appropriate.
Change scores between responses at baseline and 6 h on the 5-point Likert scale items and the VAS were calculated by subtracting the baseline value from the 6-h value. These change scores were categorized as improvement, worsening and no change. Fisher's exact tests were used to compare the 3 groups by either definition on changes in the 5-point Likert scale and on the VAS in both the upright and supine positions. Separate one-way analysis of variance (ANOVA) models were used to determine if there were any significant differences between the groups based on 6-h changes for the 5-point Likert and VAS in both the upright and supine positions. Fisher's exact tests were used since some of the expected cell counts were small (<5). ANOVA was used when three or more groups of a continuous variable were compared. For ease in interpretation, the change scores were reverse coded so that a positive score indicated improvement. Following a significant group effect, unadjusted pairwise comparisons were made between the groups. Least square means and standard errors were reported from the models. Kruskal Wallis tests were also used to look for overall group differences; as the results agreed with the ANOVA results, they were not presented. To determine concordance between the anchor scale and the 5-point Likert and VAS, a kappa (k) statistic was calculated and presented in the tables with 95% CI. Given multiplicity of testing, we used the false discover rate (FDR) to determine which values were significant at FDR ¼ 0.05. 23 All analyses were performed using SAS, version 9.4 (SAS, Inc., Cary, NC). Fig. 1 demonstrates the derivation of the final patient subset for analysis.
Results

Baseline characteristics
Of the 776 patients enrolled, 491 had both a final diagnosis of AHF and baseline/6 h self-reported dyspnea; 93 reported 'minimally improved' and 7 reported 'minimally worse' by 7-point Likert scale 6 h after enrollment. Table 1 shows the baseline characteristics of patients grouped by response on the 7-point Likert. Groups were more similar than different, however the minimal worse group was quite small (n ¼ 7), limiting any comparisons. Several notable characteristics and differences are highlighted below. The average age for the minimally improved group was 68 (SD AE 15) vs. 63 (SD AE 16) in the no change group vs. 62 years (SD AE 11) in the minimally worse group. Slightly more than half of the patients were male. Most patients had a prior history of HF, however there were significantly more obese patients in the minimally worse group. Patients who reported minimal improvement had a lower mean oxygen saturation at baseline (93.5 SD AE 4.9) compared to 96.6 (SD AE 2.4) in the minimally worse group, and had more loop diuretic use (P < 0.05 for all). Large differences were also noted in baseline 5-point Likert responses. Those who reported 'minimally improved' were more likely to have worse dyspnea at baseline. (P ¼ 0.0067). Supplemental Table 1 shows the characteristics for patients with any improvement or any worsening by 7-point Likert. Similar to the 'minimally improved or worse' group, few patients (n ¼ 25) reported feeling worse at 6 h. Table 2 shows the proportion of patients at 6 h who reported 'minimally worse,' 'no change,' and 'minimally better' scores by 7-point Likert relative to the categorized 6-h change in the VAS and 5-point Likert scales in both the upright and supine positions.
Anchor scale based changes
Although there are significant differences between groups (P < 0.01 for all), a sizable proportion of patients in every response category demonstrated discordant results. Patients who reported 'minimally worse' may have reported 'improved' by an alternate scale. Specifically, in Table 2 , of those patients who reported 'minimally improved' by 7-point Likert, 37.5% reported improved by 5-point Likert. However, 65.6% reported improved by VAS in the same upright position. Table 3 shows the proportion of patients who reported any improvement, no change, and any worsening at 6 h by 7-point Likert and the corresponding frequencies of patients' response by 5-point and VAS.
For patients who reported any improvement by 7-point Likert, they were more likely to report feeling improved by alternate scales. However, the results were inconsistent in regards to reporting 'minimally worse': many patients reported feeling improved by the alternate scale. Overall, there was poor concordance between the scales.
Minimally clinical important difference
Please see Supplemental Table 2 for a detailed description of each scale response at baseline and 6-hours and relative to the 7-point Likert.
The 6-h change in 5-point Likert scale and VAS, relative to our criterion standard of the MCID d a one-category change in the 7-point Likert scale at 6 h d are reported in Table 4 .
Although a significant MCID for improvement was observed, the MCID for worsening was not statistically significant. Changes in position seem to amplify the difference for improvement. A 10.5 mm (SE 20 mm) change in VAS was the minimal clinical significant improvement difference in the upright position, but 14.5 mm (SE 20 mm) was in the supine position. When patients who reported mild, moderate, or marked improvement or worsening were categorized into 'any improvement, no change, or any worsening,' the associated change in VAS was 24.7 mm (SD 1.1) in the upright position and 20.2 mm (SD 1.3) in the supine positions. For the upright position only, a change of 10.8 mm (SD 4.3) in VAS was associated with any worsening (Table 4 ). In addition, Table 4 also reports the change relative to the 5-point Likert scale. Although some significant differences were seen, given the 5-point scale was an ordinal scale, no difference reached the 1-point threshold, with the exception of 'any improvement. ' Of note, to account for the multiplicity of testing, we used the false discover rate (FDR) to determine which values were significant at FDR ¼ 0.05. 23 Based on this criterion, all 16 P-values reported remain significant.
Discussion
In this secondary analysis from the URGENT-Dyspnea registry, a minimal clinical important improvement in dyspnea was slightly greater than 10 mm by VAS d in both the upright and supine positions at 6 h after initial assessment. Of note, the MCID for VAS in the supine position was greater (14.5 mm) compared to VAS in the upright position (10.5 mm). We have previously reported the effect of positioning on dyspnea response, observing that supine positioning more robustly captures the symptom. 8 No significant MCID in terms of worsening was observed, however. This was driven primarily by the lack of patients who felt worse. We did not find the MCID for the 5-point Likert scale however, irrespective of position. Although easier to administer, the Likert scale may measure dyspnea differently. 8, 10 Alternatively, the categorical responses may not discriminate dyspnea sufficiently. We, along with others, have reported differences between the scales despite the same population. 7, 8 Overall, the characteristics of patients who improved, did worse, or reported no change in dyspnea were largely similar. However, we did find patients who were obese, had lower oxygen saturation at baseline and more loop diuretic use were more likely to improve. Although speculative, patients with worse signs or symptoms may have been treated more aggressively and may have had greater opportunity to improve.
To the best of our knowledge, the only other study to explore the MCID in AHF was conducted in ED patients by Ander et al. 15 Using a similar methodology of a 1-point difference in a 5-point VAS as the criterion standard for the MCID, Ander et al enrolled 74 patients from a single center, and found 21.1 mm to be the MCID for both a 'little less difficulty breathing' and a 'little more difficulty breathing.' 15 Patients were assessed every 20 min to a maximum of 2 h, unlike our study, which did a single assessment at 6 h. Differences between this study and our analysis may have been driven by the frequency of assessments, the short timeframe over which to assess the MCID, geographical variation, or baseline differences in dyspnea severity. We had previously shown that dyspnea improves rapidly within the first 6 h of therapy. 8 This method of utilizing one scale to determine the MCID in another scale d anchor based method d has been previously used in AHF 15 as well as pain scales. 16 In fact, significant differences in VAS pain perception, 13 mm on a 100 mm scale, 17 are remarkably similar to our findings. This further supports the importance of our findings and supports patient reported dyspnea as an appropriate physiologic endpoint in AHF studies, commensurate to that of the experience of pain. Although attempts to correlate a subjective response with objective criteria are understandable, 11 the patients' response continues to be an important perspective. For a symptom such as dyspnea, the patients' response may be the only valid one. 24 However, the MCID may differ based on the phenotype of AHF studied, the timing of assessment, and the setting in which it is assessed. 24 Thus, continued work is needed to better understand the MCID in AHF. Unlike the MCID, when 'any worsening' or 'any improvement' was used as the criterion standard, a much greater change in VAS was noted. Interestingly, 'any worsening' was associated with improvement by VAS. This finding was also observed with the 5-point Likert. For both scales, this paradoxical finding was attenuated by position. Although there was still improvement, a smaller proportion reported improvement in supine vs. upright position. Overall, the numbers of patients who reported worse dyspnea was small. Another related finding was the lack of concordance between the scales. As discussed in a prior analysis, 10 such discordance suggests each scale may capture different aspects of this subjective symptom. Enthusiasm for dyspnea as an endpoint has waned in clinical trials. 12 While it was a primary or co-primary endpoint in initial AHF trials, it is more often a secondary endpoint in current large clinical trials. In part, this is due to the difficulty of achieving a substantial effect over usual therapy. 12 However, failure to achieve a differential effect with novel therapies does not mitigate its importance to patients. Additionally, failure to identify a MCID may have also contributed to the waning interest in dyspnea as a trial endpoint. In other fields, such as asthma or COPD, where dyspnea is also a predominant symptom, multiple scales and MCID's are well established. As a result, dyspnea remains a key endpoint. 25 However, although MCID for dyspnea in the chronic setting of COPD exist, there is actually no MCID for COPD exacerbations. 26 Future work to confirm our findings are needed.
In addition, whether achieving the MCID is associated with outcomes, such as mortality and re-hospitalization, will also require further study. Likely, dyspnea will be one component of a larger risk stratification instrument. Although trialists' enthusiasm for dyspnea has waned, clinicians, caregivers, and patients want to feel better. 27 At the present time, patients who fail to have even a minimum improvement in dyspnea should be further assessed to confirm the correct diagnosis or under treatment.
Limitations
Our study has several limitations. As a secondary analysis, unmeasured confounders may significantly impact our findings. The total number of patients who reported minimal improvement or worsening was also small. Larger numbers may have yielded different results or more narrow confidence intervals. However, our study is one of the larger studies conducted in the ED setting to examine the MCID. In addition, other MCID's have been driven largely by improvement. 28 Our study also uses only a single anchor based method to determine the MCID. Although the anchor is well established in AHF clinical trials, 13 we did not specifically address other key domains, such as construct and content validity. Further, how to set the anchor remains debated. Pain scales have used one point changes on one scale as the anchor for another scale. Whether the measure is accurate and reliable has also been debated. Despite these limitations, dyspnea remains an important endpoint for AHF trials. Our hope is that proposing an MCID spurs further research. More frequent measurements may have also yielded different results. Other work describes certain patients may have limited somatic awareness, such as the elderly. 29, 30 Thus, their response to symptoms or recognition of symptoms may be one reason why responses vary across scales. Although our average age of patients was >60 years, this was significantly lower than the average age of patients reported in larger registries. Finally, how patients and investigators utilize the terms 'dyspnea' and 'shortness of breath' may not have been the same. For the purposes of our study, we used the terms interchangeably, though they may not be interchangeable to patients. To mitigate this limitation, patients were asked the same questions each time using the same word, to avoid mixing the two terms.
Conclusion
Dyspnea is the most common symptom in patients presenting with AHF. A 10.5 mm change is the MCID for a 6-h dyspnea improvement in ED patients with AHF. As a patient reported outcome, a better understanding of the MCID may inform future studies targeting this symptom.
